The U.S. Department of State on Thursday announced plans to bring lenacapavir — a potentially game-changing innovation for HIV prevention — to 2 million people by 2028.
Through the U.S. President’s Emergency Plan for AIDS Relief, or PEPFAR, the State Department will partner with countries with the largest burden of HIV and AIDS “over the coming months to co-develop strategies for distributing lenacapavir, with a focus on preventing mother-to-child transmission,” according to the news release.
Gilead Sciences, the company that developed the drug, is offering lenacapavir “at no profit” as part of the initiative, said its chairman and CEO, Daniel O’Day.
Printing articles to share with others is a breach of our terms and conditions and copyright policy. Please use the sharing options on the left side of the article. Devex Pro members may share up to 10 articles per month using the Pro share tool ( ).
About the author
Jenny Lei Ravelo@JennyLeiRavelo
Jenny Lei Ravelo is a Devex Senior Reporter based in Manila. She covers global health, with a particular focus on the World Health Organization, and other development and humanitarian aid trends in Asia Pacific. Prior to Devex, she wrote for ABS-CBN, one of the largest broadcasting networks in the Philippines, and was a copy editor for various international scientific journals. She received her journalism degree from the University of Santo Tomas.
